We are excited to honor and celebrate our Vice President of R&D Dan Ammon and his recent inauguration into the National Academy of Engineering (NAE). Dan brings more than 30 years of experience in biomedical device research and development to Collagen Matrix, Inc.
Election to the NAE is among the highest professional distinctions accorded to an engineer. Academy membership honors those who have made outstanding contributions to “engineering research, practice, or education, including, where appropriate, significant contributions to the engineering literature” and “the pioneering of new and developing fields of technology, making major advancements in traditional fields of engineering, or developing/implementing innovative approaches to engineering education.”
“I am deeply humbled and honored to be named a member of the National Academy of Engineering,” said Dan. “I am grateful to the hundreds of colleagues, mentors and friends who have contributed to this election. I would like to especially thank my family, who supported me greatly over this thirty-year journey.”
Dan holds a Ph.D. in Chemistry from the University at Buffalo. The teams he has led have been part of launching more than 60 products in the medical device community (including more than 10 here at CMI under his leadership!) Dan is also a co-inventor on 80 patent and patent applications.
Dan will be formally inducted and recognized during the NAE’s annual meeting on October 1, 2023. Learn more about the NAE and its distinguished members here: NAE Website – Home
About Collagen Matrix, Inc.
Collagen Matrix, Inc. is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration. Founded in 1997, Collagen Matrix is headquartered in Oakland, New Jersey and develops proprietary products that are sold to OEM customers on either a contract or private label basis across orthopedic, sports medicine, dental, and neurosurgery end markets. The company also offers partnership opportunities including distribution, contract product development, and contract manufacturing services. For more information, please visit www.collagenmatrix.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 40 healthcare companies encompassing over 200 total transactions. The firm has raised over $6 billion in limited partner commitments since inception. For more information, please visit www.lindenllc.com.
Careers
Looking for a career with purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our careers page to learn more about what sets Regenity apart.
See open postions
Related posts
Read More
Regenity Biosciences Receives 510(k) Clearance for RejuvaKnee™, a Groundbreaking Regenerative Meniscus Implant Device to Redefine the Standard of Care
PARAMUS, N.J., Oct. 8, 2024 /PRNewswire/ — Regenity Biosciences, a global leader in…
Read More
Read More
Regenity Biosciences Receives Regulatory Approval for Collagen Dental Membrane in China After First-of-its-Kind Breakthrough Clinical Study
Multicenter Clinical Study Demonstrates Benefits of Regenity’s Novel Crosslinked Collagen…
Read More
Read More
GUIDOR Portfolio
Click this link to learn about Guidor, our synthetic bone grafting system.
Read More
Let’s connect
Learn how to transform patient recovery through unique platforms and processes.